Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference.
The conference will take place on May 20, 2025, at the Nasdaq World Headquarters in New York City. Mike Catelani, who serves as President and CFO of Anixa, will deliver a presentation at 11:00 AM ET and will be available for one-on-one meetings throughout the conference.
Interested parties can access the presentation through a webcast link provided by the company. This investor conference appearance represents an opportunity for Anixa to showcase its developments in cancer-focused biotechnology to the investment community.
Positive
- Company leadership presenting at a major biotech investor conference at Nasdaq headquarters, increasing visibility
- One-on-one meeting opportunities with investors indicating active engagement with the investment community
Negative
- None.
News Market Reaction – ANIX
On the day this news was published, ANIX gained 1.45%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.
Details of the presentation are as follows:
Event: H.C. Wainwright 3rd Annual BioConnect Investor Conference
Date: May 20, 2025
Time: 11:00 AM ET
Location: Nasdaq World Headquarters in
Webcast: https://journey.ct.events/view/2e96a581-093d-44bf-a5dd-80652b7ba490
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-hc-wainwright-3rd-annual-bioconnect-investor-conference-on-may-20th-302442607.html
SOURCE Anixa Biosciences, Inc.
FAQ
When is Anixa (ANIX) presenting at the H.C. Wainwright BioConnect Conference 2025?
How can investors watch Anixa's (ANIX) BioConnect Conference presentation?
Who will represent Anixa (ANIX) at the 2025 H.C. Wainwright Conference?
What type of company is Anixa (ANIX) presenting at BioConnect 2025?
Will Anixa (ANIX) offer investor meetings at the H.C. Wainwright Conference?
